iRhythm Technologies has set a bold revenue target of $675 million to $685 million for 2025, as announced during its recent financial update. The company is focusing on expanding its reach in the healthcare sector through various strategic initiatives.
One key strategy is targeting primary care physicians, which in 2023 accounted for about 21% of new U.S. Zio XT and Zio monitor registrations. Additionally, the company's Zio AT technology has advanced with FDA clearance for two 510(k) submissions, enhancing its capabilities. Reuters highlighted iRhythm's efforts to expand internationally, with ventures in four European countries, gaining Japanese regulatory approval, and forging a strategic partnership with BioIntelliSense.
iRhythm is also integrating its systems with Epic Aura, having launched four healthcare systems in the fourth quarter of 2024, with broader plans for 2025. Moreover, the company has begun shipments of Zio monitors for home enrollment patients, aiming to improve service accessibility. These strategies collectively underpin iRhythm's ambitious 2025 revenue aspirations.